Ana Isabel Teruel

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Laura Rosiñol, Albert Oriol, Ana Isabel Teruel et al. · Blood · 2012 · 485 citations · Full text

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

Sara Alonso, Laura Magnano, Miguel Alcoceba et al. · British Journal of Haematology · 2017 · 76 citations · Full text

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

Laura Rosiñol, Albert Oriol, Ana Isabel Teruel et al. · Leukemia · 2017 · 67 citations

Hematological Malignancy, Transplantation, Marrow Transplantation +10

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Paula Arana, Bruno Paiva, Noemí Puig et al. · Blood · 2015 · 65 citations

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2019 · 62 citations